DXCM Inks Deal With Nanowear to Boost CGM Application Beyond Diabetes
DexCom's recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic ...
Zacks.com on MSN10h
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
Dexcom advanced the launch of Stelo, its over-the-counter product for non-insulin type 2 diabetes, pre-diabetes, and ...
Medscape11d
Dexcom’s 15-day CGM Adds Wear Time, Accuracy to Current G7
Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...
15.5-day G7 integrated continuous glucose monitor in adults with diabetes shows positive results
In a new study in the journal Diabetes Technology & Therapeutics (DTT), investigators evaluated the accuracy of the 15.5-day ...
DXCM Stock Gains Following New Data on Upcoming G7 CGM Sensor
DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost ...
Nasdaq9d
DXCM Stock Gains Following New Data on Upcoming G7 CGM Sensor
DexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) conference 2025.
Medical Xpress11d
15.5-day G7 integrated continuous glucose monitor in adults with diabetes shows positive results
"We conclude that the Dexcom 15-day G7 CGM is accurate and safe for use up to 15.5 days in adults with diabetes with a 27-minute warm-up," stated the investigators.